

Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB: 6/2/1968
Sex: Male
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Collection Date: 01/01/2017 12:34

Polychlorinated Biphenyls (PCB) Panel, Congeners, Serum or Plasma

ARUP test code 2013230

PCB Congener 28	<p>None Det mcg/L Serum or Plasma Reporting Limit: 0.020 mcg/L</p> <p>U.S. Population (NHANES 2003-2004) is generally less than 0.068 mcg/L (assumes serum density of 1.024 g/mL) Canadian Population (Health Canada 2007-2009) is generally less than 0.05 mcg/L Analysis by Gas Chromatography/Tandem Mass Spectrometry (GC-MS/MS)</p>
PCB Congener 44	<p>None Det mcg/L Serum or Plasma Reporting Limit: 0.010 mcg/L</p> <p>U.S. Population (NHANES 2003-2004) is generally less than 0.032 mcg/L (assumes serum density of 1.024 g/mL) Analysis by Gas Chromatography/Tandem Mass Spectrometry (GC-MS/MS)</p>
PCB Congener 52	<p>None Det mcg/L Serum or Plasma Reporting Limit: 0.010 mcg/L</p> <p>Comment: Substance(s) known to interfere with the identity and/or quantity of the reported result: 2,3',5',6-Tetrachlorobiphenyl (PCB 73) U.S. Population (NHANES 2003-2004) is generally less than 0.044 mcg/L (assumes serum density of 1.024 g/mL) Analysis by Gas Chromatography/Tandem Mass Spectrometry (GC-MS/MS)</p>
PCB Congener 66	<p>None Det mcg/L Serum or Plasma Reporting Limit: 0.010 mcg/L</p> <p>Comment: Substance(s) known to interfere with the identity and/or quantity of the reported result: 3,3',5,5'-Tetrachlorobiphenyl (PCB 80) U.S. Population (NHANES 2003-2004) is generally less than 0.025 mcg/L (assumes serum density of 1.024 g/mL)</p>

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example
ARUP Accession: 22-137-103255
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Page 1 of 4 | Printed: 10/19/2022 7:36:26 AM

Canadian Population (Health Canada 2007-2009) is generally less than 0.03 mcg/L
Analysis by Gas Chromatography/Tandem Mass Spectrometry (GC-MS/MS)

PCB Congener 74

None Det mcg/L

Serum or Plasma
Reporting Limit: 0.020 mcg/L

Comment:
Substance(s) known to interfere with the identity and/or quantity of the reported result:
2,3,4,5-Tetrachlorobiphenyl (PCB 61)
U.S. Population (NHANES 2003-2004) is generally less than 0.15 mcg/L (assumes serum density of 1.024 g/mL)
Canadian Population (Health Canada 2007-2009) is generally less than 0.10 mcg/L
Analysis by Gas Chromatography/Tandem Mass Spectrometry (GC-MS/MS)

PCB Congener 101

None Det mcg/L

Serum or Plasma
Reporting Limit: 0.010 mcg/L

Comment:
Substance(s) known to interfere with the identity and/or quantity of the reported result:
2,2',3,4,6'-Pentachlorobiphenyl (PCB 89)
U.S. Population (NHANES 2003-2004) is generally less than 0.033 mcg/L (assumes serum density of 1.024 g/mL)
Canadian Population (Health Canada 2007-2009) is generally less than 0.03 mcg/L
Analysis by Gas Chromatography/Tandem Mass Spectrometry (GC-MS/MS)

PCB Congener 118

None Det mcg/L

Serum or Plasma
Reporting Limit: 0.020 mcg/L

Comment:
Substance(s) known to interfere with the identity and/or quantity of the reported result:
2,3,3',4,5-Pentachlorobiphenyl (PCB 106)
U.S. Population (NHANES 2003-2004) is generally less than 0.22 mcg/L (assumes serum density of 1.024 g/mL)
Canadian Population (Health Canada 2007-2009) is generally less than 0.12 mcg/L
Analysis by Gas Chromatography/Tandem Mass Spectrometry (GC-MS/MS)

PCB Congener 138

None Det mcg/L

Serum or Plasma
Reporting Limit: 0.040 mcg/L

Comment:
Substance(s) known to interfere with the identity and/or quantity of the reported result:
2,3,3',4,4',6-Hexachlorobiphenyl (PCB 158);
2,3,3',4',5,6-Hexachlorobiphenyl (PCB 163);
2,3,3',4',5',6-Hexachlorobiphenyl (PCB 164)
U.S. Population (NHANES 2003-2004) for PCB congeners 138 and 158 is generally less than 0.48 mcg/L

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example
ARUP Accession: 22-137-103255
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Page 2 of 4 | Printed: 10/19/2022 7:36:26 AM

(assumes serum density of 1.024 g/mL)
Canadian Population (Health Canada 2007-2009) for PCB
congener 138 only is generally less than 0.28 mcg/L
Analysis by Gas Chromatography/Tandem Mass
Spectrometry (GC-MS/MS)

PCB Congener 153

None Det mcg/L

Serum or Plasma
Reporting Limit: 0.080 mcg/L

U.S. Population (NHANES 2003-2004) is generally less
than 0.63 mcg/L (assumes serum density of 1.024 g/mL)
Canadian Population (Health Canada 2007-2009) is
generally less than 0.54 mcg/L
Analysis by Gas Chromatography/Tandem Mass
Spectrometry (GC-MS/MS)

PCB Congener 156

None Det mcg/L

Serum or Plasma
Reporting Limit: 0.010 mcg/L

U.S. Population (NHANES 2003-2004) is generally less
than 0.10 mcg/L (assumes serum density of 1.024 g/mL)
Canadian Population (Health Canada 2007-2009) is
generally less than 0.07 mcg/L
Analysis by Gas Chromatography/Tandem Mass
Spectrometry (GC-MS/MS)

PCB Congener 180

None Det mcg/L

Serum or Plasma
Reporting Limit: 0.080 mcg/L

U.S. Population (NHANES 2003-2004) is generally less
than 0.54 mcg/L (assumes serum density of 1.024 g/mL)
Canadian Population (Health Canada 2007-2009) is
generally less than 0.49 mcg/L
Analysis by Gas Chromatography/Tandem Mass
Spectrometry (GC-MS/MS)
This test was developed and its performance
characteristics determined by NMS Labs. It has not
been cleared or approved by the US Food and Drug
Administration.
Testing performed at NMS Labs, Inc.
200 Welsh Road
Horsham, PA 19044-2208
CLIA 39D0197898

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
PCB Congener 28	22-137-103255	5/17/2022 8:13:00 AM	5/19/2022 10:22:11 AM	5/24/2022 3:24:00 PM
PCB Congener 44	22-137-103255	5/17/2022 8:13:00 AM	5/19/2022 10:22:11 AM	5/24/2022 3:24:00 PM
PCB Congener 52	22-137-103255	5/17/2022 8:13:00 AM	5/19/2022 10:22:11 AM	5/24/2022 3:24:00 PM
PCB Congener 66	22-137-103255	5/17/2022 8:13:00 AM	5/19/2022 10:22:11 AM	5/24/2022 3:24:00 PM
PCB Congener 74	22-137-103255	5/17/2022 8:13:00 AM	5/19/2022 10:22:11 AM	5/24/2022 3:24:00 PM
PCB Congener 101	22-137-103255	5/17/2022 8:13:00 AM	5/19/2022 10:22:11 AM	5/24/2022 3:24:00 PM

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example
ARUP Accession: 22-137-103255
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Page 3 of 4 | Printed: 10/19/2022 7:36:26 AM

PCB Congener 118	22-137-103255	5/17/2022 8:13:00 AM	5/19/2022 10:22:11 AM	5/24/2022 3:24:00 PM
PCB Congener 138	22-137-103255	5/17/2022 8:13:00 AM	5/19/2022 10:22:11 AM	5/24/2022 3:24:00 PM
PCB Congener 153	22-137-103255	5/17/2022 8:13:00 AM	5/19/2022 10:22:11 AM	5/24/2022 3:24:00 PM
PCB Congener 156	22-137-103255	5/17/2022 8:13:00 AM	5/19/2022 10:22:11 AM	5/24/2022 3:24:00 PM
PCB Congener 180	22-137-103255	5/17/2022 8:13:00 AM	5/19/2022 10:22:11 AM	5/24/2022 3:24:00 PM

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example
ARUP Accession: 22-137-103255
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Page 4 of 4 | Printed: 10/19/2022 7:36:26 AM